Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo.

BACKGROUND

Upadacitinib (UPA), an oral selective Jak inhibitor, showed significantly greater facial repigmentation than placebo as assessed by Facial Vitiligo Area Scoring Index (F-VASI) in a phase 2 clinical trial. A nested substudy explored a 3-dimensional (3D) imaging platform as an objective tool to quantify facial vitiligo repigmentation.

METHODS

Adults with nonsegmental vitiligo received 6, 11, or 22 mg UPA or placebo for 24 weeks (period 1). For weeks 24-52 (period 2), UPA-treated patients continued UPA at assigned doses; patients receiving placebo switched to 11 or 22 mg UPA. In this substudy, efficacy was assessed by the percentage change from baseline in facial vitiligo area with 3D imaging and F-VASI.

RESULTS

The substudy included 27 patients. Patients receiving UPA showed facial repigmentation at weeks 24 and 52 as assessed by 3D imaging and F-VASI. There was a high correlation between 3D imaging and F-VASI measurements at baseline (r = 0.85; P < .0001). At week 24, there was a high correlation (r = 0.71; P = .0003) between the percentage change from baseline in 3D imaging and F-VASI measurements, which diminished by week 52 (r = 0.01; P = .9600).

CONCLUSIONS

3D imaging shows potential as an objective tool for evaluating changes in facial vitiligo after UPA treatment.